Unlike Any Other Blood-based Tumor Marker
The DiviTum® TKa test quantifies the level of thymidine kinase activity in the bloodstream from proliferating tumor cells. This generates a DiviTum activity score which can offer important insights about the proliferative status of a patient’s disease.
Next-Level Monitoring of mBC Patients
The DiviTum® TKa test is an innovative tumor TK activity (TKa) profile test for early prognosis and prediction of mBC treatment outcomes in postmenopausal HR+ mBC patients.
Fills the Current Imaging Gap
The DiviTum® TKa test can provide clinicians with information about changes in tumor cell proliferation in response to therapy many months before a change in tumor volume is detectable by imaging.
– Assesses non-measurable disease that may not be detected with conventional imaging.
– With measurable disease, assessing TKa may complement and improve diagnostic accuracy when imaging results are equivocal.
